Comparative study of chemotherapy protocols for lymphoma in dogs

Abstract

Lymphoma (lymphosarcoma) is a malignant lesion of the lymphatic system. At the moment, cases of lymphoma among small pets have become more frequent. In this regard, literature data were studied and a chemotherapy protocol for dogs with lymphoma was developed. The study involved 20 companion dogs who were treated from September 2021 to September 2022. To make an accurate diagnosis, a history of life and anamnesis of animal disease was collected, computed tomography was performed to assess the extent of the lesion and the metastatic potential of lymphoma, and a biopsy was taken for histological examination. After receiving data confirming lymphoma, 10 companion dogs were prescribed a course of chemotherapy using the drugs etoposide, doxorubicin, vincristine, prednisolone (newly developed HOPE protocol), which were administered once a week for 19 weeks. In parallel, studies were carried out on 10 companion dogs during the same period of time, which were treated according to the well-known CHOP protocol, using cyclophosphamide, doxorubicin, vincristine, prednisolone, which is the standard treatment for lymphoma. According to the results of the study, we found that the median survival of dogs with lymphoma treated with the HOPE protocol was 302 days, and the life expectancy under the CHOP protocol was 235 days, while the animals experienced the occurrence of cystitis, polyuria and polydipsia, which was not manifested during treatment the HOPE protocol.